Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults

British Journal of Haematology

Volumn 161, Issue 3, 2013, Pages 406-410

  Phillips, Christine L ^a   Davies, Stella M ^a   Mcmasters, Richard ^a   Absalon, Michael ^a   O'Brien, Maureen ^a   Mo, Jun ^a   Broun, Randall ^b   Moscow, Jeffrey A ^c   Smolarek, Teresa ^a   Garzon, Ramiro ^d   Blum, William ^a   Schwind, Sebastian ^d   Marcucci, Guido ^d   Perentesis, John P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b JEWISH HOSPITAL   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukaemia; Decitabine; Epigenetic; Paediatric; Relapsed acute myeloid leukaemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLOFARABINE; CYTARABINE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; KLEBSIELLA INFECTION; LEUKEMIA RELAPSE; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG EVALUATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; NEOPLASM PROTEINS; NEUTROPENIA; REMISSION INDUCTION; RNA, NEOPLASM; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84876165672     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12268     Document Type: Article

References (15)

1. Blum, W., Klisovic, R.B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S.M., Heerema, N.A., Murgo, A., Chan, K.K., Grever, M.R., Byrd, J.C. & Marcucci, G. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology, 25, 3884-3891.
2. Blum, W., Garzon, R., Klisovic, R.B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., Mickle, J., Devine, H., Kefauver, C., Devine, S.M., Chan, K.K., Heerema, N.A., Bloomfield, C.D., Grever, M.R., Byrd, J.C., Villalona-Calero, M., Croce, C.M. & Marcucci, G. (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences of the USA, 107, 7473-7478.
3. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
4. Christman, J.K. (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 21, 5483-5495.
5. Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W.G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J.-P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood, 108, 3271-3279.
6. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C.E., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., Havelange, V., Volinia, S., Blum, W., Rush, L.J., Perrotti, D., Andreeff, M., Bloomfield, C.D., Byrd, J.C., Chan, K., Wu, L.C., Croce, C.M. & Marcucci, G. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113, 6411-6418.
7. Issa, J.-P.J., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J. & Kantarjian, H.M. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 103, 1635-1640.
8. Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., Ferrajoli, A., Wierda, W., Shan, J., Davis, J., Giles, F., Saba, H.I. & Issa, J.P. (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 109, 52-57.
9. Kim, D.Y., Lee, J.H., Park, Y.H., Kim, S.D., Choi, Y., Lee, S.B., Lee, K.H., Ahn, S.Y., Lee, Y.S., Seol, M., Kang, Y.A., Jeon, M., Jung, A.R. & Lee, Y.J. (2011) Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplantation, 47, 374-379.
10. Kroeger, H., Jelinek, J., Estecio, M.R., He, R., Kondo, K., Chung, W., Zhang, L., Shen, L., Kantarjian, H.M., Bueso-Ramos, C.E. & Issa, J.P. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood, 112, 1366-1373.
11. Mims, A., Walker, A.R., Huang, X., Sun, J., Wang, H., Santhanam, R., Dorrance, A.M., Walker, C., Hoellerbauer, P., Tarighat, S.S., Chan, K.K., Klisovic, R.B., Perotti, D., Caligiuri, M.A., Byrd, J.C., Chen, C.S., James Lee, L., Jacob, S., Mrózek, K., Bloomfield, C.D., Blum, W., Garzon, R., Schwind, S. & Marcucci, G. (2012) Increased anti-leukemic activity of decitabine via AR-42- induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia, Doi: 10.103/leu.2012.342 [Epub ahead of print].
12. Plimack, E.R., Kantarjian, H.M. & Issa, J.P. (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leukemia Lymphoma, 48, 1472-1481.
13. Rohner, A., Langenkamp, U., Siegler, U., Kalberer, C.P. & Wodnar-Filipowicz, A. (2007) Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leukemia Research, 31, 1393-1402.
14. Sigalotti, L., Altomonte, M., Colizzi, F., Degan, M., Rupolo, M., Zagonel, V., Pinto, A., Gattei, V. & Maio, M. (2003) 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood, 101, 4644-4646.
15. Silverman, L.R., Fenaux, P., Mufti, G.J., Santini, V., Hellström-Lindberg, E., Gattermann, N., Sanz, G., List, A.F., Gore, S.D. & Seymour, J.F. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer, 1-6.